Maternal Intake of Eggs and Infant Neurodevelopment
University of Kansas Medical Center · NCT07583186
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · Women only
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- January 1, 2026
- Record last updated
- May 13, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The fetal brain requires DHA, choline, lutein, and zeaxanthin (L/Z) for development, dependent on maternal intake during pregnancy. However, many pregnant women do not meet daily requirements through diet or prenatal vitamins. Egg yolks are rich in choline, and women who consume eggs daily are more likely to meet the adequate intake of 450 mg/day. A recent study by Christifano et al. found that maternal egg and neuroprotective nutrient intake predicted neurodevelopment at 32 and 36 weeks of gestation. This study aims to determine if fetal neurodevelopment is enhanced among women who consume a prenatal diet emphasizing egg consumption (EGG) versus a healthy prenatal diet education control group (HPD). Women between 12-20 weeks' gestation will be randomized into EGG and HPD groups. The EGG group will receive education on the importance of prenatal choline and egg consumption and be encouraged to consume 10-14 eggs per week. The HPD group will receive education on a healthy prenatal diet. Both groups will be encouraged to take a DHA supplement, and dietary intake of choline, L/Z, and DHA will be collected. Fetal heart rate variability will be measured at 36 weeks gestation and infant EEGs will be conducted postnatally to examine brain function. Increasing prenatal egg consumption is both economical and feasible to boost prenatal choline intake, promote offspring neurodevelopment, and guide prenatal dietary recommendations.
Being studied: Egg Supplementation; Healthy Prenatal Diet
Conditions: Pregnancy Related
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Pregnant females ≥18 years of age
- 12 to 20-weeks' gestation at enrollment
- No serious illnesses likely to confound study outcomes
- Consuming 3 eggs/week or less at enrollment and willing to increase consumption during the study
- Singleton gestation
- Available by telephone and text
Exclusion Criteria
- Less than 18 years at enrollment
- Gestational age at enrollment \<12 or >20 weeks
- Any serious illness likely to confound study outcomes
- Consuming more than 3 eggs per week at enrollment
- Unable/unwilling to consume eggs until delivery or egg allergy
- Expecting multiple infants
- No access to telephone or text
Recruiting US locations
The University of Kansas Medical Center
Kansas City, KS 66160
Site contact: Nicole Mathis, MS · 913-588-1906
Study contacts (from the official record)
- Nicole Mathis, MS · 913-588-1906 · nmathis@kumc.edu
- Lara Bennett, MS · 913-945-9149 · lbennett@kumc.edu
Similar studies in Kansas
All nutrition & metabolism studies in Kansas →- RecruitingPhase 3
A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
Hoffmann-La Roche
- Location
- Topeka, KS + 121 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
Hoffmann-La Roche
- Location
- Kansas City, KS + 112 other US sites
- Eligibility basics
- Ages 18–75
- RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Akero Therapeutics, Inc
- Location
- Topeka, KS + 131 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingPhase 3
LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
Boehringer Ingelheim
- Location
- Topeka, KS + 154 other US sites
- Eligibility basics
- Ages 18+